A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital


  • Jayakumar Sreenivasan MBBS Student, Govt. Medical College, Kozhikode, Kerala, India
  • Seema P. Mohamedali Department of Pharmacology, Govt. Medical College, Kozhikode, Kerala, India http://orcid.org/0000-0002-6741-027X




Adverse drug reaction, Chemotherapeutic agents, Cost analysis, Lung cancer, Performance status


Background: Lung cancer is the deadliest type of cancer for both men and women. The study was aimed at learning and comparing the toxicities of various chemotherapeutic regimens for the treatment of carcinoma lung, which will help in the implementation of counter measures to avoid development of toxicities, with a constant vigil on the patients during chemotherapeutic cycles. This study also aimed at searching into the added economic burden to the unfortunate patient, who is already suffering from a deadly disease. Study also targeted at evaluating the performance status of the patients receiving the chemotherapy.

Methods: The Adverse Drug Reactions (ADR) data was collected from 40 patients receiving chemotherapy for locally advanced unresectable carcinoma lung from the cancer wards of a tertiary care hospital over a period of 2 months. ADRs were graded according to WHO guidelines and their performance statuses were assessed using the Zubrod’s performance scale. Cost analysis of chemotherapeutic regimens was also carried out.

Results: On comparison, alopecia and peripheral neuropathy were significantly more common with carboplatin-paclitaxel combination compared to other regimens (p value<0.005). Cost analysis reveals that the most commonly employed carboplatin-paclitaxel combination is more affordable when compared to the newer highly expensive agents but is costlier than cisplatin based chemotherapy. Also, carboplatin-paclitaxel combination offers a reasonably good performance status.

Conclusions: Thus, carboplatin-paclitaxel combination is the preferred regimen for palliation in advanced NSCLC, especially in the older patients.


K Park. Park’s textbook of Preventive and Social Medicine 20th Edition, M/s Banarsidas Bhanot publishers; 2011:360-370.

Stephen J. McPhee, Maxine A. Papadakis, Eds. Michael W. Rabow, Associate Ed. CURRENT Medical Diagnosis and Treatment. The McGraw-Hill Companies, Inc. 2011.

Karnofsky DA, Ableman WH, Craver LF, Burchenal JH. The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer. 1948;1:634-56.

Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Journal of Clinical Epidemiology. 1960 Jan 1;11(1):7-33.

Vincent T DeVita, Jr. MD Theodore S Lawrence MD, PhD Steven A Rosenberg MD, PhD Ronald A DePinho MD Robert A Weinberg PhD. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology: Lippincott Williams and Wilkins; 2011.

Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian journal of pharmacology. 2010 Feb;42(1):40.

Ogawara M, Kawahara M, Hosoe S, Atagi S, Kawaguchi T, Okishio K, et al. A Feasibility Study of Paclitaxel 225 mg/m2 and Carboplatin AUC= 6 in Untreated Advanced Non-small Cell Lung Cancer Patients in Japan. Japanese Journal of Clinical Oncology. 2002 Feb 1;32(2):48-53.

Bergsagel DE, Robertson GL, Hasselback R. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Canadian Medical Association Journal. 1968 Mar 16;98(11):532.

Palappallil DS, Nair BL, Jayakumar KL, Puvathalil RT. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian Journal of Cancer. 2011 Jan 1;48(1):68.

Torre DM, Lamb GC, Van Ruiswyk J, Schapira RM, Kochar MS. Kochar's Clinical Medicine for Students: Lippincott Williams and Wilkins; Feb 13, 2008.

Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. British Journal of Cancer. 1993 Apr;67(4):773.

Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. Jul 28 2004; 292(4):470-84.

Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman Jr CA, et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. Journal of Clinical Oncology. 1991 Jul;9(7):1157-62.

Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. JNCI: Journal of the National Cancer Institute. 1993 Mar 3;85(5):384-8.

Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. JNCI: Journal of the National Cancer Institute. 1993 Mar 3;85(5):388-94.

Shiller JH, Harrington D, Sandler A, Belani C, Langer C, Krook J, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncology. 2000;19:1a (abstr 2).

Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Ann Oncology. 2000;11:799-805.

Natale RB. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncology. 1996;23(16):51-64.

Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther. 2006;2:14-6.

Touraine F, Sainte JL, Boumédiène A, Ndikumwenayo F, Decroisette C, Melloni B, et al. Investigation of allergic reactions to platinum salts. Revue des maladies respiratoires. 2006 Nov;23(5 Pt 1):458-62.

Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. 2007 Jun 6;99(11):847-57.

Davis HL, Ramirez G, Korbitz BC, Ansfield FJ. Advanced lung cancer treated with cyclophosphamide. Diseases of the Chest. 1969 Dec 1;56(6):494-500.

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine. 1996 Jan 4;334(1):1-6.

Toschi L, Cappuzzo F. Dovepress Journal: Onco Targets and Therapy. Gemcitabine for the treatment of advanced non-small cell lung cancer. 2009;2:209-217.

Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. Journal of clinical oncology. 1995 Nov;13(11):2842-50.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. Sep 3 2009;361(10):947-57.




How to Cite

Sreenivasan, J., & Mohamedali, S. P. (2018). A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 7(4), 676–683. https://doi.org/10.18203/2319-2003.ijbcp20181169



Original Research Articles